India’s top drug advisory panel has approved Natco Pharma’s request to make and sell erdafitinib tablets by skipping a Phase-III trial but needing a post-launch study in Phase IV
Simple ethical design
India’s top drug advisory panel has approved Natco Pharma’s request to make and sell erdafitinib tablets by skipping a Phase-III trial but needing a post-launch study in Phase IV
